| Remicade as TNF suppressor in patients with myelodysplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 15370256 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low-risk myelodysplastic syndromes (MDS) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles. Median age was 68 years, 33 had primary MDS, 14 had refractory anemia (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts. Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles. Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2. Two patients had multi-lineage responses, 2 had > 100% increase in absolute neutrophils, 1 had > 1 gm/dl increase in hemoglobin, 1 had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses (> 50% reduction in + 8 and 20q-metaphases respectively). We conclude that Remicade may have a variety of activities in low risk MDS patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future. |
| | |
Authors:
|
A Raza; A Candoni; U Khan; L Lisak; S Tahir; F Silvestri; J Billmeier; M Imran Alvi; M Mumtaz; S Gezer; P Venugopal; P Reddy; N Galili |
Related Documents
:
|
19772796 - Poor to modest agreement between rheumatoid arthritis response measures in clinical pra... 11704286 - Hla-drb1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and he... 3437426 - Retropharyngeal hematoma as a new cause of acute upper airway obstruction in rheumatoid... 17896806 - Bone mineral density in older adult patients with rheumatoid arthritis: an analysis of ... 18280636 - Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. 11299066 - The acute effects of body position strategies and respiratory therapy in paralyzed pati... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 45 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-16 Completed Date: 2005-04-19 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: England |
Other Details:
|
Languages: eng Pagination: 2099-104 Citation Subset: IM |
Affiliation:
|
Section of Myeloid Diseases, Rush University, Chicago, IL 60612-3515, USA. azra_raza@rush.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anemia, Refractory Antibodies, Monoclonal / administration & dosage*, toxicity Chromosome Aberrations Cytogenetic Analysis Disease Progression Female Humans Male Myelodysplastic Syndromes / complications, drug therapy*, genetics Pancytopenia / drug therapy Patient Compliance Pilot Projects Remission Induction Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Grant Support | |
ID/Acronym/Agency:
|
P01CA 75606/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Tumor Necrosis Factor-alpha; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bcl-2 and immunoglobulin gene rearrangements in patients with malaria related chronic splenomegaly.
Next Document: Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B...